Beta-blockers are a group of drugs widely used to treat cardiovascular diseases. Over the past two years, the market for these drugs has been growing – not only in value terms but also in physical volume. The main action of these drugs is to block beta-adrenergic receptors, which reduces heart rate and contractility, lowers the heart muscle’s oxygen demand and decreases blood pressure. This effect makes beta-blockers indispensable for treating arterial hypertension, coronary heart disease, cardiac arrhythmias and chronic heart failure.
All beta-blockers are prescription-only and require individual selection and medical supervision, as only a physician can determine the optimal dosage and treatment regimen based on each patient’s specific characteristics.
The analysis covers drugs from ATC group [C07] “Beta-blocking agents”.
According to DSM Group’s monthly retail audit of the Russian pharmaceutical market, from April 2025 through March 2026 inclusive, Russians spent 25.4 billion roubles on beta-blockers – an increase of 9.3% year-on-year. Consumption in packs rose 0.3% to 114.5 million units over the 12‑month period. The weighted average price per pack reached 222.1 roubles. The bulk of sales in the group consist of drugs from the list of vital and essential medicines.
Over the past 12 months, Russian pharmacies stocked beta-blockers from 51 manufacturers (263 SKUs). Approximately 90% of the turnover in roubles came from drugs containing three active substances: bisoprolol, metoprolol and nebivolol.
Most beta-blockers are available as tablets (including film-coated, extended-release and prolonged-release formulations), which makes them easy to take and allows precise dosing. This dosage form helps patients adhere to their doctor’s instructions and makes long-term therapy as convenient as possible. As a result, packs containing 30 or 60 tablets are the most in-demand on the market.
The sales mix is shifting in favour of locally produced drugs, primarily from Russian manufacturers. However, foreign companies still hold a large share for several key INNs: metoprolol (76.2% in rouble terms), nebivolol (66.8%) and sotalol (91.8%).
Four Russian companies made it into the top ten beta-blocker manufacturers, two of them posting double-digit growth, with PFC Renewal taking the top spot.
Domestic company PFC Renewal led the rouble-growth ranking among the top ten beta-blocker manufacturers. For the second consecutive year, Renewal posted strong growth: in the period from April 2025 to March 2026, its sales volume rose 53.4% compared with the same period a year earlier. The company’s beta-blocker portfolio expanded from four to five brands over the year, adding Nebivolol Renewal 5 mg tablets in pack sizes No. 30 and No. 60, registered in early 2025.
Renewal’s positive momentum was driven by increased demand for Bisoprolol Renewal (+81.6%), Anaprilin Renewal (+43.4%) and Metoprolol Renewal (+29.2%). Each of these drugs is available in pharmacies in various dosages and pack sizes.
The top three growth leaders also include foreign manufacturers of original drugs. In second place is Italian corporation A. Menarini (+18.5%) with its tablet-form drug Nebilet (INN nebivolol). Third is AstraZeneca (+14.4%) with two metoprolol-based brands: Betaloc Zok (+14.4%) in film-coated extended-release tablets, and Logimax (+2.5%) in film-coated prolonged-release tablets.
